Interim Analyses and Data Monitoring in Clinical Study Report
ICH E3 section 11.4.2.3 calls for interim analyses and data-monitoring activity relevant to the study results to be identified, including their timing, role, and implications for interpretation. Keep this CSR results/reporting scope separate from a general methods-only discussion of stopping rules or trial-governance policy.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Report relevant interim analyses and monitoring arrangements, including when they occurred and how they affected decisions or interpretation where applicable.
Key details
Core IssueICH E3 section 11.4.2.3 calls for interim analyses and data-monitoring activity relevant to the study results to be identified, including their timing, role, and implications for interpretation.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Keep this CSR results/reporting scope separate from a general methods-only discussion of stopping rules or trial-governance policy.
Further guidance
Content
Report relevant interim analyses and monitoring arrangements, including when they occurred and how they affected decisions or interpretation where applicable.
Purpose
Report relevant interim analyses and monitoring arrangements, including when they occurred and how they affected decisions or interpretation where applicable.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 9.8 calls for changes made after the study began to the conduct of the study or planned analyses to be described, including timing, reasons, decision process, responsibility, available data, and interpretive implications as applicable. This section is broader than a statistical-methods subsection: it covers material study-conduct changes as well as planned-analysis changes, while detailed statistical methods remain in their dedicated section.
ICH E3 section 9.6 calls for data quality assurance information relevant to the reliability and integrity of the reported study data. This CSR-specific section does not replace broader trial quality-management guidance and should not be conflated with the separate appendix for interlaboratory standardization documentation.
ICH E3 section 11.1 calls for the exact patients included in each efficacy analysis to be precisely defined and for relevant exclusions and their timing or rationale to be accounted for. This CSR subsection reports the sets actually analyzed; it is distinct from protocol-stage prespecification of analysis populations and from general study-population selection criteria.
ICH E3 calls for demographic and other baseline characteristics in the core efficacy evaluation and also identifies patient-level demographic data among the report’s appendix listings. This page is specific to ICH E3 clinical-study-report presentation and is distinct from general manuscript advice about a baseline-characteristics table.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 section 11.4.4 addresses relationships among dose, measured drug concentration, and clinical response when those data are relevant to interpreting efficacy. This results-level relationship analysis is distinct from documenting how doses were selected or how concentrations were measured during study conduct.
ICH E3 section 11.4.5 calls for efficacy discussion of drug-drug and drug-disease interactions when they are relevant to the study findings. Do not turn the subsection into a general pharmacology interaction catalogue; keep it tied to interactions evaluated or observed in the reported clinical study.
